Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Oramed Pharmaceuticals Inc. announced detailed results from its previously completed Phase 2a trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. The preliminary results of this trial were originally announced on Jan. 30, 2014.
The detailed results were presented Thursday by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, at the 2014 GTC Diabetes Summit, taking place in Cambridge, Massachusetts. The trial was conducted in the United States under a Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
http://www.dddmag.com/news/2014/04/oramed-details-oral-insulin-trial-results
The detailed results were presented Thursday by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, at the 2014 GTC Diabetes Summit, taking place in Cambridge, Massachusetts. The trial was conducted in the United States under a Food and Drug Administration (FDA) Investigational New Drug (IND) protocol.
http://www.dddmag.com/news/2014/04/oramed-details-oral-insulin-trial-results